? Strong cash position of S$35.7 million, boosted by IPO proceeds
? Clinical trials on track
Singapore, 11 November 2015 – Specialty pharmaceutical company iX Biopharma Ltd. (“iX Biopharma” or, together with its subsidiaries, “the Group”) has reported results for the first quarter ended 30 September 2015 (“1Q16”) which continue to reflect prudent cash management, as it prepares for the next phase (“Phase 2c”) of clinical trial for WafermineTM, the world’s first oral-sublingual analgesic employing ketamine as its active compound. The results of the earlier Phases 2a and 2b clinical trials involving single doses of WafermineTM confirmed a rapid onset of pain relief, along with good tolerability. Following the positive results, the Company commenced a Phase 2c study in October 2015. This is a multi-dose study of the efficacy of WafermineTM alone and in combination with opioids in subjects undergoing bunionectomy.
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
